Hello and welcome,

Backed by a group of visionary investors, Type6 Tx was founded around a tight-knit team of Parke-Davis-era veteran drug-discoverers who have come together to address hallmarks of cancers that continue to evade today’s therapeutics.

To that end, we target kinases where they are most vulnerable: their idle, metastable OFF-states. Beyond countering tumor escape mechanics, this has substantial advantages over inhibiting the catalytic function of the ON-state: unmatched selectivity, full depth of inhibition, and unprecedented durability in the face of adaptive tumor response.

Applied to our CDK2i lead program, this approach has generated a new class of powerful kinase inhibitors that distinguish themselves from competitor assets in almost every way. And we are excited about what this will mean for patients down the road.

Traction on additional high-value kinase targets suggest general applicability across much of the human kinome as a target space. While the near term focus is on advancing our CDK2i lead program, thoughtful target-selection and strategic collaborations are top of mind as we set our sights to building out a robust pipeline of wholly owned and partnered programs.

Stay tuned and feel free to reach out,

Gert Kiss

Founding CEO, Type6 Therapeutics, Inc.